All In Biotech

NDA 021530 · Avondale Pharms

Meloxicam

Meloxicam · Oral · Nonsteroidal Anti-inflammatory Drug

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jun 1, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

142

48 Phase 3, 10 recruiting

FAERS reports

58,670

33,720 serious, 3,800 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) Meloxicam oral suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer...

What it is approved for

From the label in effect Sep 25, 2026.

Meloxicam oral suspension is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older ( 1.3 ) 1.1 Osteoarthritis (OA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam oral suspension is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older [see Clinical Studies (14.2) ].

Mechanism: Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam oral suspension, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro . Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 11, 2005 Supplement 1 · Efficacy · priority review LetterLabel
  • Jun 1, 2004 Original approval · Type 3 - New Dosage Form OrphanLabelReviewLetter
1 products under this application
  • MELOXICAM · MELOXICAM 7.5MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Meloxicam" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6,182
  • pain4,886
  • fatigue4,833
  • arthralgia4,413
  • nausea4,028
  • headache3,527
  • diarrhoea3,424
  • dyspnoea2,829
  • dizziness2,784
  • off label use2,751
  • pain in extremity2,683
  • malaise2,612

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004211
2005311
2006189
2007335
2008525
2009649
2010836
20111,126
20121,711
20131,806
20142,246
20153,478
20164,710
20174,207
20184,905
20195,286
20205,035
20213,923
20223,747
20233,558
20243,586
20253,661
20262,629

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Meloxicam (Meloxicam)

2024 spending

$51.5M

Beneficiaries

4,115,676

12,080,589 claims

Per beneficiary

$13

$0.08 per unit

View as table
YearSpending
2020$59,063,564
2021$65,346,593
2022$69,716,600
2023$68,061,312
2024$51,524,957

Part D: Meloxicam (Meloxicam, Submicronized)

2024 spending

$16.2M

Beneficiaries

6,756

21,714 claims

Per beneficiary

$2,402

$15.48 per unit

View as table
YearSpending
2020$0
2021$3,068,861
2022$10,179,681
2023$15,164,100
2024$16,224,920

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 449 on PubMed

Sponsor: Avondale Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.